Elisabeth Digifico

ORCID: 0000-0003-0107-1401
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immune cells in cancer
  • Cancer Immunotherapy and Biomarkers
  • Epigenetics and DNA Methylation
  • Bone and Dental Protein Studies
  • Occupational and environmental lung diseases
  • Phagocytosis and Immune Regulation
  • Radiomics and Machine Learning in Medical Imaging
  • Immune Cell Function and Interaction
  • IL-33, ST2, and ILC Pathways
  • Cell Image Analysis Techniques
  • Cancer Cells and Metastasis
  • Pleural and Pulmonary Diseases
  • bioluminescence and chemiluminescence research
  • Cancer Research and Treatments
  • Digestive system and related health
  • Nanoplatforms for cancer theranostics
  • Nanoparticle-Based Drug Delivery
  • Graphene and Nanomaterials Applications
  • PARP inhibition in cancer therapy
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • HER2/EGFR in Cancer Research
  • Inflammatory Biomarkers in Disease Prognosis
  • Cytokine Signaling Pathways and Interactions

IRCCS Humanitas Research Hospital
2021-2025

Humanitas University
2017-2022

Istituti di Ricovero e Cura a Carattere Scientifico
2017-2022

Background Tumor-associated macrophages (TAMs) play a key immunosuppressive role that limits the ability of immune system to fight cancer and hinder antitumoral efficacy most treatments currently applied in clinic. Previous studies have evaluated response triggered by (TLR) agonists, such as poly(I:C), imiquimod (R837) or resiquimod (R848) monotherapies; however, their combination for treatment has not been explored. This study investigates macrophage reprogramming poly(I:C) combined with...

10.1136/jitc-2021-002408 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2021-09-01

Tumor-Associated Macrophages (TAMs) are the main immune component of tumor stroma with heterogeneous functional activities, predominantly suppressing response and promoting progression, also via secretion different factors. Among these, GPNMB (Glycoprotein non-metastatic B) is usually associated disease progression in several types. Malignant pleural mesothelioma (MPM) a severe neoplasia poor prognosis, characterized by an abundancy TAMs, testifying presence long-lasting inflammation which...

10.1186/s12967-025-06407-4 article EN cc-by-nc-nd Journal of Translational Medicine 2025-04-18

Abstract Macrophage plasticity is the ability of mononuclear phagocytes to change phenotype, function, and genetic reprogramming upon encounter specific local stimuli. In tumor microenvironment, Tumor‐Associated Macrophages (TAMs) acquire an immune‐suppressive tumor‐promoting phenotype. With aim re‐educate TAMs antitumor effectors, in this study, we used two immunestimulatory compounds: TLR7 agonist Imiquimod (IMQ) TLR3 Poly(I:C). To better mimic vitro response TAMs, Tumor‐Conditioned...

10.1002/eji.201847888 article EN cc-by European Journal of Immunology 2019-02-19

Abstract A considerable proportion of cancer patients are resistant or only partially responsive to immune checkpoint blockade immunotherapy. Tumor‐Associated Macrophages (TAMs) infiltrating the tumor stroma suppress adaptive responses and, hence, promote evasion. Depletion TAMs modulation their protumoral functions is actively pursued, with purpose relieving this state immunesuppression. We previously reported that trabectedin, a registered antitumor compound, selectively reduces monocytes...

10.1002/eji.202149379 article EN cc-by-nc-nd European Journal of Immunology 2021-09-27

Background Malignant Pleural Mesothelioma (MPM) is an aggressive cancer of the mesothelial lining associated with exposure to airborne non-degradable asbestos fibers. Its poor response currently available treatments prompted us explore biological mechanisms involved in its progression. MPM characterized by chronic non-resolving inflammation; this study we investigated which inflammatory mediators are mostly expressed tumor samples from patients, a focus on cytokines, chemokines and matrix...

10.3389/fimmu.2023.1116430 article EN cc-by Frontiers in Immunology 2023-06-16

Malignant Pleural Mesothelioma (MPM) is an aggressive tumor of the pleural lining that usually identified at advanced stages and resistant to current therapies. Appropriate pre-clinical mouse models are pivotal importance study its biology. Usually, cells have been injected intraperitoneally or subcutaneously. Using three available murine mesothelioma cell lines with different histotypes (sarcomatoid, biphasic, epithelioid), we set up a simplified model in vivo growth orthotopically by...

10.3390/cancers12082136 article EN Cancers 2020-08-01
Coming Soon ...